Table 2.

Incidence Rates (IR) of Psychotic Readmission During the Follow-up with Specific Antipsychotics

Antipsychotics	No. of Events	Person-years (PY; %)	IR/10-PY (95% CI)
Total with use of antipsychotics	143 191	277 849 (100.00)	5.15 (5.13–5.18)
(1) Monopharmacy	98 137	213 190 (76.73)	4.60 (4.57–4.63)
First-generation oral antipsychotics	19 941	45 082 (16.23)	4.42 (4.36–4.48)
Chlorpromazine	1225	2281 (0.82)	5.37 (5.07–5.67)
Chlorprothixene	72	130 (0.05)	5.54 (4.26–6.82)
Flupentixol	2439	4922 (1.77)	4.95 (4.76–5.15)
Haloperidol	5271	10 452 (3.76)	5.04 (4.91–5.18)
Levomepromazine	16	27 (0.01)	5.87 (2.99–8.75)
Loxapine	225	614 (0.22)	3.66 (3.18–4.14)
Pimozide	310	298 (0.11)	10.40 (9.24–11.55)
Sulpiride	8823	22 765 (8.19)	3.88 (3.79–3.96)
Thioridazine	309	735 (0.26)	4.20 (3.73–4.67)
Trifluoperazine	871	2 189 (0.79)	3.97 (3.71–4.24)
Zuclopenthixol	380	669 (0.24)	5.68 (5.11–6.25)
First-generation LAIs	2536	6571 (2.36)	3.86 (3.71–4.01)
Flupentixol LAI	1373	3103 (1.12)	4.42 (4.19–4.66)
Fluphenazine LAI	184	554 (0.20)	3.32 (2.84–3.80)
Haloperidol LAI	831	2483 (0.89)	3.35 (3.12–3.57)
(Zu)clopenthixol LAI	148	431 (0.16)	3.43 (2.88–3.99)
Second-generation oral antipsychotics	73 575	156 343 (56.27)	4.71 (4.67–4.74)
Amisulpride	5306	14 077 (5.07)	3.77 (3.67–3.87)
Aripiprazole	4370	12 129 (4.37)	3.60 (3.50–3.71)
Clotiapine	1216	1981 (0.71)	6.14 (5.79–6.48)
Clozapine	10 747	19 965 (7.19)	5.38 (5.28–5.48)
Lurasidone	18	14 (0.01)	12.80 (6.89–18.72)
Olanzapine	9552	22 248 (8.01)	4.29 (4.21–4.38)
Paliperidone	3281	6553 (2.36)	5.01 (4.84–5.18)
Quetiapine	11 825	17 529 (6.31)	6.75 (6.62–6.87)
Risperidone	21 622	51 499 (18.53)	4.20 (4.14–4.25)
Ziprasidone	1173	2384 (0.86)	4.92 (4.64–5.20)
Zotepine	4465	7964 (2.87)	5.61 (5.44–5.77)
Second-generation LAIs	2078	5161 (1.86)	4.03 (3.85–4.20)
Paliperidone LAI 28	483	823 (0.30)	5.87 (5.34–6.39)
Risperidone LAI	1595	4338 (1.56)	3.68 (3.50–3.86)
Other	7	33 (0.01)	2.12 (0.55–3.69)
(2) Polypharmacy	45 054	64 659 (23.27)	6.97 (6.90–7.03)